{"ok":true,"entity":{"id":"alteogen","name":"Alteogen","entityType":"company","officialName":"Alteogen Inc.（알테오젠）","canonicalName":"Alteogen","displayName":"Alteogen","category":"韓国のバイオ医薬企業（皮下注射化技術Hybrozyme）","shortDescription":"Alteogenは韓国・大田広域市儒城区に本社を置くバイオ企業で、ヒアルロニダーゼを用いて静脈内投与を皮下投与に切り替えるHybrozyme技術とALT-B4（berahyaluronidase alfa）を開発している。2026年9月2日にNovartisとALT-B4を用いた皮下注製剤のオプション・ライセンス契約を締結したと報じられ、2026年7月時点ではKOSPI移管の予備審査申請を一時延期してKOSDAQに残留している。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.alteogen.com/","updatedAt":"2026-10-29T04:31:31.488Z","secondaryClusters":[],"alias":["알테오젠","Alteogen Inc."],"searchKeywords":["アルテオジェン","Alteogen","알테오젠","Hybrozyme","ハイブロザイム","ALT-B4","berahyaluronidase alfa","皮下注射製剤","ヒアルロニダーゼ","KOSDAQ 196170"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}